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131I-metaiodobenzylguanidine (
131I-MIBG) is a licensed palliative treatment for patients with metastatic neuroendocrine tumours. We
have retrospectively assessed the consequences of
131I-MIBG therapy in 48 patients (30 gastroenteropancreatic, 6 pulmonary, 12
unknown primary site) with metastatic neuroendocrine tumours attending Royal Liverpool University Hospital between 1996 and
2006. Mean age at diagnosis was 57.6 years (range 34–81).
131I-MIBG was administered on 88 occasions (mean 1.8 treatments, range
1–4). Twenty-nine patients had biochemical markers measured before and after
131I-MIBG, of whom 11 (36.7%) showed 450%
reduction in levels post-therapy. Forty patients had radiological investigations performed after
131I-MIBG, of whom 11(27.5%)
showed reduction in tumour size post-therapy. Twenty-seven (56.3%) patients reported improved symptoms after
131I-MIBG
therapy. Kaplan–Meier analysis showed significantly increased survival (P¼0.01) from the date of first
131I-MIBG in patients who
reported symptomatic benefit from therapy. Patients with biochemical and radiological responses did not show any statistically
significant alteration in survival compared to non-responders. Eleven (22.9%) patients required hospitalisation as a consequence of
complications, mostly due to mild bone marrow suppression.
131I-MIBG therefore improved symptoms in more than half of the
patients with metastatic neuroendocrine tumours and survival was increased in those patients who reported a symptomatic response
to therapy.
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Neuroendocrine tumours (NETs) are rare and their aetiology is
poorly understood. Many tumours grow slowly, although some can
grow very rapidly (Modlin et al, 2003, 2005). They express
neuroendocrine differentiation markers, have secretory character-
istics and may present with hypersecretory syndromes (Plockinger
et al, 2004; Ramage et al, 2005). Unlike patients with adenocarci-
nomas at the same sites, patients with NETs tend to experience a
longer indolent duration of their condition. Although the
incidence of NETs is low (3–4 cases per 100000 per annum)
(Ramage et al, 2005), the good prognosis of many with these
tumours has resulted in an increasing prevalence.
Many patients present when their tumour has already metasta-
sised. In such patients, alleviation of hormonal symptoms and
prolongation of survival are key goals (Plockinger et al, 2004;
Ramage et al, 2005). Palliative treatment options include surgical
resection of the primary tumour if symptomatic, treatment of liver
metastases (by debulking surgery, hepatic artery embolisation or
radiofrequency ablation), chemotherapy, interferon-a, somatosta-
tin analogues and radionuclide therapies (Plockinger et al, 2004;
Ramage et al, 2005).
131I-metaiodobenzylguanidine (
131I-MIBG) is a licensed systemic
treatment for the palliation of patients with metastatic NETs.
131I-MIBG is a guanethidine derivative, structurally similar to
noradrenaline and thus is accumulated in tissues arising from
neural crest cells (Wafelman et al, 1994).
131I-MIBG is transported
by vesicular monoamine proteins and is concentrated in
intracellular storage vesicles (Kolby et al, 2003). It is thought that
emission of ionising radiation at this site results in tumour decay
(Mukherjee et al, 2001; Rose et al, 2003; Pasieka et al, 2004). This
therapy has been used to treat NETs of various types, including
gastroenteropancreatic NETs (Pathirana et al, 2001; Pasieka et al,
2004; Safford et al, 2004; Sywak et al, 2004; Buscombe et al, 2005),
paraglangliomas (Mukherjee et al, 2001; Safford et al, 2003;
Fitzgerald et al, 2006), phaeochromocytomas (Castellani et al,
2000; Rose et al, 2003; Safford et al, 2004; Fitzgerald et al, 2006),
medullary carcinoma of the thyroid (Castellani et al, 2000, 2003;
Mukherjee et al, 2001) and neuroblastomas (Howard et al, 2005;
Matthay et al, 2007). A number of previous studies had
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sdemonstrated significant symptomatic benefit in 40–60% of
patients with metastatic NETs following
131I-MIBG therapy
(Safford et al, 2004; Sywak et al, 2004), in a safe and cost-effective
manner (Pathirana et al, 2001).
Few studies have, however, investigated whether
131I-MIBG also
increases the survival of patients with metastatic NETs. We have
therefore assessed the efficacy and toxicity of
131I-MIBG therapy in
a 10-year cohort of patients with metastatic NETs.
METHODS
Patients
A total of 58 patients were identified from the records of the
Nuclear Medicine department of Royal Liverpool and Broadgreen
University Hospitals NHS Trust as having received
131I-MIBG
therapy between May 1996 and May 2006. The study was registered
at the hospital audit department and approval was obtained to
perform the study. All patients were selected for
131I-MIBG therapy
following discussion at a multidisciplinary meeting when the
disease was metastatic, patients were symptomatic, curative
surgical treatment was not possible and patients showed strong
tumour uptake of
123I-MIBG by scintigraphy. Additional treat-
ments were considered on an individual basis following discussion
at the multidisciplinary team meeting.
All case notes were obtained and a retrospective case note
analysis was performed. The following parameters were recorded
for each case: patient demographics; date of diagnosis; primary site
of tumour, site of metastases and details of histology; previous
treatments administered; blood and urine results (including full
blood count, serum electrolytes, liver function tests, serum
chromogranin A, fasting gut hormone profile, 24h urinary 5HIAA
concentration) and results of all imaging studies performed
(including computerised tomography (CT), ultrasound, magnetic
resonance imaging (MRI),
111In-octreotide and
123I-MIBG scans).
In addition, the dates of all
131I-MIBG therapies were recorded and
details of all blood tests and imaging studies performed post-
therapy to monitor the side effects and therapeutic effects of each
treatment cycle were kept.
Of the 58 patients who received
131I-MIBG therapy, 48 patients
were identified as having metastatic gastroenteropancreatic or
pulmonary NETs and these individuals were included in the study.
The remainder had other tumour types (mostly paraganglioma,
phaeochromocytoma, and medullary carcinoma of the thyroid)
and were excluded from further analysis. Neuroendocrine tumours
were diagnosed in 33 (68.8%) cases on the basis of confirmatory
histology, but in 15 (31.2%) cases no biopsy was performed and the
diagnosis was established on the basis of positive imaging studies
(such as CT,
123I-MIBG or
111In-Octreotide scans), along with
significantly elevated titres of biochemical markers (24h urinary
5HIAA and/or serum chromogranin A) in patients presenting with
symptoms compatible with the carcinoid syndrome.
Analysis of response to treatment
All patients received 7.4 GBq
131I-MIBG for each treatment cycle,
and thyroid blockade was given using 170mg of potassium iodate
per day per treatment cycle. Response to
131I-MIBG therapy was
assessed using standard World Health Organization (WHO)
criteria in a similar manner to previous studies (Safford et al,
2004). A course of treatment was considered as the completion of
therapy from the first to the last treatment of
131I-MIBG.
Symptomatic responders were defined as patients reporting either
complete resolution or a subjective decrease in the intensity of
symptoms. These symptoms included abdominal pain, flushing,
bloating, diarrhoea, weight loss, fatigue, sweats, breathlessness,
vomiting, haemoptysis and anorexia. Patients were defined as
biochemical responders if serum chromogranin A and/or 24h
urinary 5HIAA levels showed either complete normalisation or a
reduction of 450% in previously elevated concentrations. A
radiological tumour response was defined as either complete
regression of tumour burden or a 425% reduction in tumour size
based on analysis of post-therapy
131I-MIBG, CT or MRI scans by a
consultant radiologist. The NCI common toxicity criteria were
used to assess the toxicity of
131I-MIBG therapy. Toxicity was
assessed by monitoring full blood count, serum electrolytes and
thyroid function tests after each dose of
131I-MIBG.
Statistical analysis
Data were stored and analyzed using the Statistical Software
Package for the Social Sciences (SPSS version 14.0). Survival is
quoted as median±s.e. Survival outcomes were plotted using the
Kaplan–Meier method. w
2 tests (Log-rank, Wilcoxon and Tarone–
Ware) were used to compare categorical variables. Statistical
significance was set at Po0.05.
RESULTS
Patient characteristics
A total of 48 patients (21 male, 27 female) were identified as having
received
131I-MIBG therapy for NETs (30 gastroenteropancreatic, 6
pulmonary, 12 with unknown site of primary tumour) (Table 1).
The mean age at diagnosis was 57.6 years (range 34–81). All
patients were identified as having metastatic disease, with liver
metastases being present in 44 (91.7%). The most common
presenting symptoms were diarrhoea, flushing and abdominal pain
(present in 60.4, 58.3 and 41.7% of patients, respectively) (Table 1).
Twenty-nine (60.4%) patients had received surgery at some point
as part of the management of their condition. Small bowel
resection was the most common procedure, being performed in 13
(27.1%) cases. Thirty-seven (77.1%) patients received short or long
acting somatostatin analogues at some stage during the course of
their treatment. Although many patients experienced some benefit
from these agents, they all had residual symptoms and the
responses described below to
131I-MIBG therapy, all occurred while
patients remained on a stable dose of somatostatin analogues. Six
(12.5%) patients had also received chemotherapy, two (4.2%)
interferon-a, one (2.1%) radiofrequency ablation of liver metas-
tases and seven (14.6%) hepatic chemoembolisation at some point
during the course of their illness.
131I-MIBG was administered to
these patients on 88 occasions (mean 1.8 treatments per patient,
range 1–4) (Figure 1). The median time from initial diagnosis to
first
131I-MIBG treatment was 38.5±9.5 months and the median
follow up post-
131I-MIBG treatment was 31.0±3.5 months (range
7–127 months).
Response to
131I-MIBG therapy
Median survival for the 48 patients was 79±7.2 months from
initial diagnosis and 46±4.6 months from first
131I-MIBG
treatment. Of the 26 patients who died during the study period,
median time from initial diagnosis to death was 57.5±6.3 months
and median time from first
131I-MIBG treatment to death was
19.5±4.7 months.
Twenty-nine patients were identified in whom records of
biochemical tumour marker measurements performed before
and after
131I-MIBG therapy could be found. These investigations
were performed while patients continued to take a stable dose of
somatostatin analogue, if they were prescribed such therapy.
Of these 29 patients, 11 (36.7%) showed 450% reduction in
concentrations of serum chromogranin A and/or 24h urinary
5HIAA post-
131I-MIBG therapy (Table 2). Similarly, 40 patients
were identified in whom reports were available for analysis of
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131I-MIBG
therapy. Eleven (27.5%) of these patients showed 425% reduction
of tumour size on post-therapy scans (Table 2). Records of
symptomatic responses to
131I-MIBG therapy were available for all
48 patients from follow up outpatient clinic letters. Twenty-seven
(56.3%) patients reported improvement in their symptoms
following
131I-MIBG therapy (Table 2).
Kaplan–Meier analysis showed significantly increased survival
(59.0±13.9 months) from the date of first
131I-MIBG treatment in
those patients who reported symptomatic benefit following
therapy compared to those who showed no improvement in
symptoms (22.0±5.3 months) (Po0.01; Figure 2A). Patients
in whom results of radiological scans post-
131I-MIBG therapy
could not be found survived for shorter periods of time (median
3.0±1.4 months) compared to those with in whom the results of
radiological follow up scans post-
131I-MIBG (median 59±7.9
months) (Po0.001) were available. This may be because the
former group of patients died before follow-up scans could be
arranged. However, there was no significant difference in survival
between those patients who showed improvement in radiological
scans (median 46±14.7 months) compared with those who
showed no change or progression on radiological scans (median
77±28.8 months) (Figure 2B). Patients identified as biochemical
responders also did not show any significant difference in survival
compared to non-responders (median survival 46.0±18.7 months
in biochemical responders compared to 46.0±1.3 months in
non-responders) (Figure 2C).
Tumours were subgrouped into those arising in the gastro-
intestinal tract, pancreas, lung and unknown primary site to assess
whether tumour site affected response to
131I-MIBG therapy. There
was no significant correlation between tumour site and either
patient survival or symptomatic, radiological or biochemical
response to
131I-MIBG therapy.
In addition, there were no significant differences between those
patients having liver resection (six patients), radiofrequency
ablation (one patient) or chemoembolisation (seven patients) of
liver metastases and the remainder of the cohort who did not have
cytoreductive liver treatment in terms of symptomatic response or
survival following
131I-MIBG therapy.
Although there was a trend towards more courses of
131I-MIBG
therapy being administered to symptomatic responders (mean 2.07
treatments) compared to symptomatic non-responders (mean 1.48
treatments), this difference was not statistically significant.
Similarly, there were no statistically significant differences in the
number of
131I-MIBG treatments administered to radiological
responders (mean 1.73 treatments) vs non-responders (mean two
treatments) and biochemical responders (mean 1.91 treatments)
vs non-responders (1.86 treatments).
Although symptomatic responders demonstrated significantly
increased survival compared to non-responders from the date of
first administration of
131I-MIBG therapy (Figure 2A), when the
survival of these patients was assessed from the date at which they
Table 1 Patient demographics
Characteristic Total (%)
Number of patients receiving
131I-MIBG 48 (100)
Female 27 (56.3)
Male 21 (43.8)
Mean age at time of diagnosis 57.6 (s.d. 10.9)
Mean age at time of first
131I-MIBG 61.7 (s.d. 10.0)
Presenting symptoms
Diarrhoea 29 (60.4)
Flushing 28 (58.3)
Abdominal pain 20 (41.7)
Weight loss 15 (31.3)
Fatigue/tiredness 8 (16.7)
Bloating/distension 7 (14.5)
Breathlessness 6 (12.5)
Vomiting 5 (10.4)
Haemoptysis 3 (6.3)
Sweats 3 (6.3)
Loss of appetite 2 (4.2)
Site of primary tumour
Small bowel 17 (33.3)
Lung 6 (12.5)
Pancreas 5 (10.4)
Caecum 3 (6.3)
Ascending colon 2 (4.2)
Liver 1 (2.1)
Stomach 1 (2.1)
Appendix 1 (2.1)
Unknown 12 (25.0)
Presence of metastases 48 (100)
Liver 44 (91.7)
Bone 4 (8.3)
Lymph node 13 (27.1)
Previous surgery 29 (60.4)
Small bowel resection 13 (27.1)
Right hemicolectomy 7 (14.6)
Other relevant resection 7 (14.6)
Shunt/bypass 7 (14.6)
Liver resection 6 (12.5)
Other treatments
Somatostatin analogues 37 (77.1)
Chemotherapy 6 (12.5)
Interferon-a 2 (4.2)
Radiofrequency ablation 1 (2.1)
Hepatic chemoembolisation 7 (14.6)
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Figure 1 Number of patients receiving 1, 2, 3 or 4 cycles of
131I-MIBG
therapy. Total patient number is 48. Mean number of treatments per
patient was 1.8.
Table 2 Clinical response to
131I-MIBG therapy
Characteristic Total (%)
Biochemical markers (24h urine 5-HIAA and/or serum
chromogranin A) measured before and after
131I-MIBG
treatment
29
450% reduction of biochemical markers
post-
131I-MIBG therapy
11/29 (36.7)
Radiological investigations performed before and after
131I-MIBG treatment
40
425% reduction in tumour size demonstrated on
post-
131I-MIBG scans
11/40 (27.5)
Symptomatic response to
131I-MIBG therapy 27/48 (56.2)
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treatment, there was no significant difference between sympto-
matic responders (median 89±26.6 months) and non-responders
(median 79±15.9 months) (Figure 3). This observation may reflect
the fact that the symptomatic responders received
131I-MIBG
treatment earlier in the course of their illness.
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Figure 2 Kaplan–Meier charts demonstrating patient survival from the date of first
131I-MIBG treatment for (A) symptomatic, (B) radiological and
(C) biochemical variables comparing responders to
131I-MIBG therapy with non-responders.
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131I-MIBG therapy
The NCI toxicity criteria were used to assess the side effects of
131I-MIBG therapy (Table 3). Twelve (25%) patients developed
haematological complications. There were seven (14.5%) cases of
anaemia (all grade 1 or 2), three (6.2%) of thrombocytopaenia (one
grade 1, one grade 2, one grade 3) and five (10.4%) of leucopenia
(all grade 1 or 2). Nine patients showed disturbance of only one
haematological parameter, whereas two developed both anaemia
and thrombocytopaenia and one developed leucopenia and
anaemia. All cases of myelosuppression resolved spontaneously.
No patient developed renal failure, and three (6.3%) developed
abnormal thyroid function tests (two hypothyroid, one hyperthy-
roid) despite thyroid blockade. One developed hypothyroidism
after their first treatment, whereas the second patient was
biochemically euthyroid after each of the first three treatments,
but became hypothyroid after the fourth. Other symptomatic
complications included nausea and vomiting, which occurred
in nine (18.8%) patients and lethargy in seven (14.6%). Eleven
(22.9%) patients required hospitalisation as a consequence of
complications, mostly for monitoring of myelosuppression and for
symptomatic relief of side effects. There was only one death within
30 days of treatment and this was due to tumour progression
rather than due to treatment side effects. No patient experienced
carcinoid crisis.
DISCUSSION
In summary, we have demonstrated that
131I-MIBG therapy
resulted in symptomatic improvement in more than half of a
group of 48 patients with metastatic NETs. Patients who reported
a symptomatic improvement also showed a 37-month increase in
median survival from the date of first
131I-MIBG administration.
Although some evidence of treatment-related toxicity was found in
up to a third of patients, this toxicity was mild and self-limiting in
most cases.
The proportion of patients experiencing symptomatic benefit
from
131I-MIBG therapy (56.3%) was similar to that reported in
previous studies (Safford et al, 2004; Sywak et al, 2004). As in one
previous similar study (Safford et al, 2004), survival after
131I-MIBG therapy was best predicted by a subjective symptomatic
response to treatment. Median survival was increased by 37
months in symptomatic responders compared to non-responders
in this study, compared to 32 months in the previous study
(Safford et al, 2004). As also previously demonstrated by Safford
et al (2004), patients who demonstrated improvement in
biochemical parameters (serum chromogranin A or 24h urine
5HIAA) or decreased tumour burden on follow up radiological
scans post-
131I-MIBG therapy showed no statistically significant
differences in survival. This finding may partly reflect the small
sample size of patients who had complete biochemical and
radiographic measurements available. Nonetheless, our data
suggest that routine monitoring of biochemical and radiographic
parameters post-
131I-MIBG therapy is unlikely to provide useful
information about an individual patient’s prognosis.
Overall median survival in our cohort of patients (79±7.2
months) was similar to that reported in previous studies. In our
study, although symptomatic responders to
131I-MIBG therapy
showed significantly increased survival compared to non-res-
ponders when assessed from the date of first
131I-MIBG treatment,
when survival of this group was assessed from the date of initial
diagnosis with a NET, there was no statistically significant
difference compared to those patients who did not demonstrate
a symptomatic response to
131I-MIBG therapy. It is therefore
possible that the responders to
131I-MIBG therapy were treated
earlier in the course of their illness. It is not currently known
whether a patient’s response to radionuclide therapies alters
during the course of disease progression. A randomised
prospective trial in a less heterogeneous group of patients would
be necessary to definitively determine whether
131I-MIBG therapy
improves overall survival in patients with metastatic NETs.
Toxicity post-
131I-MIBG therapy was not infrequent, occurring
in 29.2% patients and leading to hospitalisation in 22.9%. Bone
marrow suppression was observed most commonly, but in most
cases this was mild (NCI grade 1 or 2) and resolved spontaneously
without specific measures. There was one death within 30 days of
treatment, but this was as a result of tumour progression rather
than due to treatment side effects. Two patients developed
hypothyroidism despite thyroid blockade.
Patients with NETs do benefit from a multidisciplinary approach
to their care. All patients should be evaluated in a standardised
manner using a range of biochemical assays as well as with
anatomical and functional imaging techniques. Several treatment
options are often possible for an individual patient at a particular
stage in the course of his/her illness and the choice of treatment
should therefore be discussed by the multidisciplinary team and
with the patient concerned. Our study confirms previous observa-
tions that
131I-MIBG therapy is a generally safe and reasonably
well-tolerated treatment option and confers symptomatic benefit
in 450% patients with metastatic NETs. Symptomatic responders
to
131I-MIBG therapy may have an improved prognosis. However,
as responders in this study were often treated earlier in the course
of their illness, current data do not confirm a significant increase
in survival from the date of initial diagnosis. It therefore appears
that the use of small-fractionated doses of
131I-MIBG probably
does not affect the overall survival of patients with metastatic
NETs, although therapy does appear to have a major effect on
symptoms in many patients. The efficacy of larger doses of
131I-MIBG should therefore be evaluated, but as this is likely to be
associated with an increased incidence of bone marrow toxicity
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Figure 3 Kaplan–Meier chart demonstrating patient survival from the
date of diagnosis in symptomatic responders to
131I-MIBG therapy
compared with non-responders.
Table 3 Toxicity of
131I-MIBG therapy
NCI toxicity
Characteristic
Number of patients
(total 48) 1 2 3 4
Hospitalisation 11 NA
Thrombocytopenia 3 0 2 1 0
Anaemia 7 0 7 0 0
Leucopenia 5 0 5 0 0
Renal impairment 0 0 0 0 0
Thyroid abnormalities 3 NA
Abbreviation: NA¼not applicable.
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novel forms of radionuclide therapy have been developed. Direct
comparisons of
131I-MIBG with other radionuclide therapies such
as
90Y-DOTATOC (Bodei et al, 2004; Forrer et al, 2006; Frilling
et al, 2006) should therefore be performed to determine the
optimal treatment regimes for individual patients.
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